Advertisement

Topics

Oxford BioMedica plc Company Profile

22:42 EST 13th December 2018 | BioPortfolio

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.


News Articles [337 Associated News Articles listed on BioPortfolio]

Oxford BioMedica Notes the Longer-Term Analyses from Pivotal Kymriah Trials, Which Showed Durable Responses Are Maintained in Patients with Advanced Blood Cancers

Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today notes an announcement by Novartis on the longer-term analyses of both the ELIANA an...

Axovant buys rights for Oxford BioMedica’s Parkinson’s candidate

Biopharmaceutical firm Axovant Sciences has agreed exclusive worldwide rights for the development and commercialisation of gene therapy company Oxford BioMedica’s...Read More... The post Axovant buy...

Oxford BioMedica: Vector Value: An Interview with Nick Woolf, SVP Corporate Strategy

Fintan Walton talks to Nick Woolf, Senior Vice President, Corporate Strategy, Oxford BioMedica, about the company’s ongoing success as it moves toward its ultimate goal of becoming a fully integrate...

Boehringer, Oxford BioMedica join on CF gene therapy project

Securing Oxford BioMedica's participation is indicative of the manufacturing hurdles present in gene therapy, particularly involving lentiviral vectors. 

Axovant, Oxford BioMedica sign $842.5m Parkinson’s disease deal

Axovant Sciences has signed an exclusive worldwide licensing agreement with Oxford BioMedica to develop and commercialise, OXB-10, to treat Parkinson’s disease.

Oxford BioMedica unveils digital initiative to streamline manufacturing

UK gene and cell therapy group Oxford BioMedica has announced a new digital framework initiative to streamline the production of next-generation medicines.

Oxford BioMedica (OXB) - Golden age for LentiVector as Axovant signs deal

Edison Investment Research - Pharmaceutical & healthcare - Oxford BioMedica: Oxford BioMedica (OXB) has signed an out-licensing deal with Axovant for its Parkinson’s disease (PD) gene therapy AX...

Oxford Biomedica inks licensing agreement with Axovant Sciences

Gene and cell therapy group Oxford BioMedica has entered into an exclusive worldwide licensing agreement with Nasdaq-listed Axovant Sciences that will see the pair develop and commercialise OXB-102...

Drugs and Medications [0 Results]

None

PubMed Articles [614 Associated PubMed Articles listed on BioPortfolio]

Leishmaniasis cutánea y embarazo.

El drama de las enfermedades tropicales desatendidas.

Cross-cultural adaptation and validation of the Romanian Oxford Shoulder Score.

The use of validated patient reported outcome scores is critical to the reporting and monitoring of the effectiveness of clinical treatment. The aim of this study was to translate and culturally valid...

BulkVis: a graphical viewer for Oxford nanopore bulk FAST5 files.

The Oxford Nanopore Technologies (ONT) MinION is used for sequencing a wide variety of sample types with diverse methods of sample extraction. Nanopore sequencers output FAST5 files containing signal ...

Clinical Trials [99 Associated Clinical Trials listed on BioPortfolio]

Oxford Partial Knee Replacement. A Randomized Clinical Trial of Three Implant Types

The purpose of this scientific study is to clarify whether there is a relationship between the appearance of radiolucent lines in bone-cement interphase of the tibial component of the diff...

Comparison of Oxford UKA and Sigma UKA With RSA.

Comparison of two unicompartmental knee arthroplasties (UKA), to see if Sigma UKA performs equally good as the Oxford UKA. The study focuses on how well the arthroplasty is fixated to the ...

A Clinical Investigation of the Oxford® Meniscal Unicompartmental Knee System

The purpose of this study is to collect information on complications and survivorship of patients implanted with the Oxford™ Meniscal Unicompartmental Knee System at multiple sites in th...

Oxford® Partial Knee Kinematics Gait Analysis Study

The objective of this study is to compare the effect on gait of unicompartmental knee arthroplasty (UKA), using the Oxford® Partial Knee, versus total knee arthroplasty (TKA), using the V...

Outcome Analysis of the Oxford Partial Knee Arthroplasty

Prospectively monitor the patients receiving the Oxford Partial knee arthroplasty

Companies [109 Associated Companies listed on BioPortfolio]

Oxford BioMedica

Oxford BioMedica advanced gene therapy techniques.

Oxford BioMedica plc

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the...

BioMedica Inc.

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was esta...

Boston Biomedica Incorporated

Boston Biomedica, Inc. is an infectious diseases management company providing products and services for the detection and treatment of infectious diseases (ID) such as AIDS, Lyme Disease, and Viral He...

Oxford Resource Partners, LP

Oxford Resource Partners, LP is a low cost producer of high value steam coal in Northern Appalachia and the Illinois Basin. Oxford markets its coal primarily to large electric utilities with coal-fir...

More Information about "Oxford BioMedica plc" on BioPortfolio

We have published hundreds of Oxford BioMedica plc news stories on BioPortfolio along with dozens of Oxford BioMedica plc Clinical Trials and PubMed Articles about Oxford BioMedica plc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Oxford BioMedica plc Companies in our database. You can also find out about relevant Oxford BioMedica plc Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record